- Home
- ANAB vs RUM Comparison
ANAB vs RUM Comparison
Compare ANAB & RUM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANAB | RUM |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ANAB | RUM |
|---|---|---|
| Price | $57.29 | $9.50 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $71.67 | N/A |
| AVG Volume (30 Days) | 374.8K | ★ 4.0M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | 80.72 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $234,603,000.00 | $100,622,320.00 |
| Revenue This Year | N/A | $209.98 |
| Revenue Next Year | $52.14 | $40.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 157.01 | 5.38 |
| 52 Week Low | $17.11 | $4.62 |
| 52 Week High | $73.30 | $10.60 |
Technical Indicators
Market Signals| Indicator | ANAB | RUM |
|---|---|---|
| Relative Strength Index (RSI) | 50.01 | 70.60 |
| Support Level | $53.46 | $5.37 |
| Resistance Level | $57.70 | $10.54 |
| Average True Range (ATR) | 2.36 | 0.75 |
| MACD | 0.18 | 0.24 |
| Stochastic Oscillator | 41.32 | 76.92 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About RUM Rumble Inc.
RUM Group Inc focused is to maximize the power of human imagination through an independent technology ecosystem built on privacy, resilience, and an open alternative to Big Tech. Rumble gives human creativity a voice, a video and media platform built for creators and audiences who value free expression. Quake AI is a cloud and AI-infrastructure business, delivering the compute, data-center capacity, and blockchain infrastructure for the agentic era.